Immune reset: CAR T-Cells take on lupus and other autoimmune diseases
Disease control
Ongoing
This early-phase study tests a one-time treatment called KYV-101, which uses a patient's own modified immune cells to target and destroy faulty B cells that drive autoimmune diseases like lupus, vasculitis, and scleroderma. Up to 24 adults will receive the therapy and be monitore…
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated May 17, 2026 06:52 UTC